Design, synthesis, and discovery of 5-((1, 3-diphenyl-1H-pyrazol-4-yl)methylene)pyrimidine-2, 4, 6(1H, 3H, 5H)-triones and related derivatives as novel inhibitors of mPGES-1. Issue 5 (1st March 2018)
- Record Type:
- Journal Article
- Title:
- Design, synthesis, and discovery of 5-((1, 3-diphenyl-1H-pyrazol-4-yl)methylene)pyrimidine-2, 4, 6(1H, 3H, 5H)-triones and related derivatives as novel inhibitors of mPGES-1. Issue 5 (1st March 2018)
- Main Title:
- Design, synthesis, and discovery of 5-((1, 3-diphenyl-1H-pyrazol-4-yl)methylene)pyrimidine-2, 4, 6(1H, 3H, 5H)-triones and related derivatives as novel inhibitors of mPGES-1
- Authors:
- Ding, Kai
Zhou, Ziyuan
Zhou, Shuo
Yuan, Yaxia
Kim, Kyungbo
Zhang, Ting
Zheng, Xirong
Zheng, Fang
Zhan, Chang-Guo - Abstract:
- Graphical abstract: Rational molecular design, followed by synthesis and in vitro activity assays for evaluating both the potency and selectivity, has led to the discovery of a set of novel, potent and selective mPGES-1 inhibitors. Abstract: Human mPGES-1 has emerged as a promising target in exploring a next generation of anti-inflammatory drugs, as selective mPGES-1 inhibitors are expected to discriminatively suppress the production of induced PGE2 without blocking the normal biosynthesis of other prostanoids including homeostatic PGE2 . Therefore, this therapeutic approach is believed to reduce the adverse effects associated with the application of traditional non-steroidal anti-inflammatory drugs (tNSAIDs) and selective COX-2 inhibitors (coxibs). Identified from structure-based virtue screening, the compound with ( Z )-5-benzylidene-2-iminothiazolidin-4-one scaffold was used as lead in rational design of novel inhibitors. Besides, we further designed, synthesized, and evaluated 5-((1, 3-diphenyl-1 H -pyrazol-4-yl)methylene)pyrimidine-2, 4, 6(1 H, 3 H, 5 H )-triones and structurally related derivatives for their in vitro inhibitory activities. According to in vitro activity assays, a number of these compounds were capable of inhibiting human mPGES-1, with the desirable selectivity for mPGES-1 over COX isozymes.
- Is Part Of:
- Bioorganic & medicinal chemistry letters. Volume 28:Issue 5(2018)
- Journal:
- Bioorganic & medicinal chemistry letters
- Issue:
- Volume 28:Issue 5(2018)
- Issue Display:
- Volume 28, Issue 5 (2018)
- Year:
- 2018
- Volume:
- 28
- Issue:
- 5
- Issue Sort Value:
- 2018-0028-0005-0000
- Page Start:
- 858
- Page End:
- 862
- Publication Date:
- 2018-03-01
- Subjects:
- Anti-inflammatory drugs -- Pyrazole -- Barbituric acid -- mPGES-1 inhibitor
Bioorganic chemistry -- Periodicals
Pharmaceutical chemistry -- Periodicals
572 - Journal URLs:
- http://www.elsevier.com/wps/find/journaldescription.cws_home/972/description#description ↗
http://www.sciencedirect.com/science/journal/0960894X ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.bmcl.2018.02.011 ↗
- Languages:
- English
- ISSNs:
- 0960-894X
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 2089.330000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 5914.xml